Comparing Acute Kidney Injury Reports Among Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)

被引：0
|
作者：
Taylor M. Patek
Chengwen Teng
Kaitlin E. Kennedy
Carlos A. Alvarez
Christopher R. Frei
机构：
[1] The University of Texas at Austin,Pharmacotherapy Division, College of Pharmacy
[2] The University of Texas Health Science Center at San Antonio,Pharmacotherapy Education and Research Center, Long School of Medicine
[3] Texas Tech University Health Sciences Center,Division of Clinical/Translational Research, Hodge School of Pharmacy
[4] South Texas Veterans Health Care System,undefined
[5] University Health System,undefined
来源：
Drug Safety | 2020年 / 43卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：17 / 22
页数：5
相关论文
共 50 条
  • [21] A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for sunitinib
    Zhang, Xusheng
    Ren, Xiuli
    Zhu, Tianyu
    Zheng, Wanjin
    Shen, Chengwu
    Lu, Cuicui
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [22] Pharmacovigilance analysis of orlistat adverse events based on the FDA adverse event reporting system (FAERS) database
    Zhu, Jinfeng
    Hu, Mianda
    Liang, Yingshi
    Zhong, Mingjun
    Chen, Zilin
    Wang, Zhenjie
    Yang, Yujia
    Luo, Ziyi
    Zeng, Wenqi
    Li, Jiahui
    Du, Yikuan
    Liu, Yi
    Yang, Chun
    [J]. HELIYON, 2024, 10 (14)
  • [23] Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database
    Zhou, Jianxing
    Wei, Zipeng
    Xu, Baohua
    Liu, Maobai
    Xu, Ruichao
    Wu, Xuemei
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [24] A real-world pharmacovigilance study of polatuzumab vedotin based on the FDA adverse event reporting system (FAERS)
    Liu, Dan
    Mao, Wei
    Hu, Bin
    Li, Xingxing
    Zhao, Quanfeng
    Zhang, Lin
    Hu, Jing
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [25] Catatonia related to tacrolimus: a real world pharmacovigilance study of FDA adverse event reporting system (FAERS) database
    Yang, Jing
    Yang, Hui
    An, Zhuoling
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024,
  • [26] Evaluating Reports of Pancreatic Malignancy and Liraglutide: A Pharmacovigilance Study of the FDA Adverse Event Reporting System
    Alvarez, Carlos A.
    Teng, Chengwen
    Mansi, Ishak
    [J]. DIABETES, 2020, 69
  • [27] Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS)
    Ma, Pan
    Pan, Xinmei
    Liu, Ruixiang
    Qu, Ya
    Xie, Linli
    Xie, Jiangchuan
    Cao, Liya
    Chen, Yongchuan
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [28] Postmarketing safety profile of brexanolone: a pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS)
    Meilian Zhang
    Wenhuo Xie
    Jianbin Li
    Jiaping Zheng
    Yu Zhou
    [J]. Archives of Women's Mental Health, 2024, 27 : 35 - 44
  • [29] Postmarketing safety profile of brexanolone: a pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS)
    Zhang, Meilian
    Xie, Wenhuo
    Li, Jianbin
    Zheng, Jiaping
    Zhou, Yu
    [J]. ARCHIVES OF WOMENS MENTAL HEALTH, 2023, 27 (1) : 35 - 44
  • [30] Comparing the difference of adverse events with HER2 inhibitors: a study of the FDA adverse event reporting system (FAERS)
    Bao, Yiwen
    Chen, Jiaju
    Duan, Luting
    Wang, Fujue
    Lai, Han
    Mo, Zeming
    Zhu, Weiliang
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
12345